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Kaposi’s sarcoma (KS) has played a pivotal role in medical history 
as one of the two diseases in which an unexpected cluster led to 
the identification of HIV/AIDS.[1] It is a tumour of the blood and 
lymphatic vessels caused by the infectious agent human herpes virus 8 
(HHV8 or Kaposi’s sarcoma virus). All four of its subtypes typically 
involve cutaneous lesions, and may additionally affect the oral cavity, 
lymph nodes and viscera. Compared with the other three subtypes 
(classic KS, African endemic KS and immunosuppression-related 
KS), HIV/AIDS-related KS (HIV-KS) is more aggressive, more likely 
to involve the lymph nodes, and more lethal.[2,3]
Antiretroviral therapy in the Western world, irrespective 
of the specific regimen, has been found to improve HIV-KS 
outcomes. [4] Highly active antiretroviral therapy (HAART), a 
further advance in treatment, has also led to improvement in 
HIV-KS outcomes.[5,6] HAART has notably been associated with 
a decrease in the incidence of HIV-KS,[5] protection against KS,[6] 
a longer time to tumour progression,[7] and improvement in both 
prognosis and survival.[8]
The national roll-out of HAART in South Africa (SA) did not 
begin until 2003. The most recent studies of HIV-KS characteristics 
and incidence in SA were conducted in the pre-HAART and early 
HAART period,[2,9,10] during which KwaZulu-Natal (KZN), a province 
of SA (population 10 million, capital city Durban), emerged as the 
epicentre of both HIV/AIDS and KS prevalence in Africa and the 
world. Now that the incidence of HIV/AIDS has levelled off and 
increasing numbers of HIV-positive patients are using HAART, it 
seemed timely to evaluate the effects of these changes in a sample of 
HIV-KS patients in KZN.
Methods
Study design and sample population
A retrospective chart analysis was performed at the oncology clinic 
at Addington Hospital (ADH), a 571-bed district- and regional-
level hospital in Durban, KZN. This site was selected because it is 
the oncology clinic to which HIV-KS patients in KZN are referred. 
Previous HIV-KS studies have also been conducted at this site, and 
its selection facilitated temporal comparisons.
Patients diagnosed with HIV-KS in 2011 had greater opportunities 
to be treated with HAART than those diagnosed in earlier years. 
We, therefore, restricted our sample to HIV-KS patients who first 
presented to the oncology clinic in 2011. We excluded patients 
whose charts lacked documentation/confirmation of HIV status or 
histological confirmation of KS, patients with KS unrelated to HIV/
AIDS, patients with more than one diagnosis of cancer, and patients 
who were not chemotherapy or radiotherapy naïve.
Ethical approval for the study was obtained from the institutional 
review board of the Nelson R Mandela School of Medicine, University 
of KwaZulu-Natal (Ref. BE338/14).
Definitions
A case of HIV-KS was defined as a patient diagnosed with HIV in 
whom histological confirmation of KS had been made. HIV-KS 
stage was based on the modified AIDS Clinical Trial Group (ACTG) 
guidelines.[11] Patients were categorised as at poor risk if they had 
visceral disease, lymphoedema or ulceration (T1), advanced immune 
suppression (CD4 count <150 cells/µL) (I1), or systemic features of 
AIDS such as a history of opportunistic infections (S1). Patients were 
HAART in hand: The change in Kaposi’s sarcoma 
presentation in KwaZulu-Natal, South Africa
L Naidoo,1 MB ChB, FCDerm (SA); J S Jacobson,2 DrPH, MPH, MBA, BA; A I Neugut,2 MPH, PhD, MD, BA;  
N C Dlova,1 MB ChB, FCDerm (SA), PhD; A Mosam,1 MB ChB, FCDerm (SA), MMed, PhD
1  Department of Dermatology, School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine,  
University of KwaZulu-Natal, Durban, South Africa
2  Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA
Corresponding author: L Naidoo (levashni.naidoo@yahoo.com)
Background. HIV/AIDS-related Kaposi’s sarcoma (HIV-KS) is a public health problem in South Africa (SA). It is AIDS defining. There 
have been no studies evaluating its prevalence since the national roll-out of highly active antiretroviral therapy (HAART).
Objective. To evaluate the effect of HAART on the disease profile of HIV-KS in KwaZulu-Natal Province (KZN), SA.
Methods. Charts of patients with histologically confirmed HIV-KS were reviewed at an oncology clinic in KZN. The significance of 
associations of HAART with age, gender, CD4 count, urban/rural residence, fungating lesions, ulceration and lymphoedema, and treatment 
delay, was determined by t-tests for normally distributed continuous variables and χ2 tests for categorical variables. Logistic regression 
models were used to analyse the association of HAART with CD4 count.
Results. Of 198 patients, 194 were documented as HIV-positive; 168 (86.6%) were on HAART at the time of their KS diagnosis. The mean 
CD4 count of 266 cells/µL was higher than that in previous studies at this site. The mean age at presentation was 36.6 (standard deviation 
10.1) years. Females presented at a younger mean age than males (p<0.001). The mean age of females on HAART was 34.7 years and that 
of males 39.0 years (p=0.003). HAART-naive patients were three times more likely than those receiving HAART (15.4% v. 4.8%) to have 
visceral involvement (p=0.03).
Conclusions. HAART use has resulted in outcome improvement. Mean age at presentation has increased in the group as a whole and for 
females in particular. The trend in mean CD4 counts has shown positive growth. Females no longer shoulder a disproportionate burden 
of disease.
S Afr Med J 2016;106(6):611-616. DOI:10.7196/SAMJ.2016.v106i6.10333
612       June 2016, Vol. 106, No. 6
RESEARCH
categorised as at good risk if they met none 
of those criteria.
Data collection, methods and tools
On request, the principal specialist who ran 
the oncology clinic at ADH gave permission 
to access the patient charts. Data were 
collected manually at the clinic because 
KZN does not have a cancer registry and 
the oncology clinic lacks a computerised 
database of patients.
The following were captured from patient 
charts: demographic characteristics (age, 
gender, race, and urban or rural residence), 
immunological status (CD4 count), clinical 
findings (opportunistic infections and the 
staging-related conditions listed above), 
and proposed initial management (HAART, 
chemotherapy, radiotherapy).
Statistical analysis
On charts that yielded the full complement 
of data, we compared patients receiving 
and not receiving HAART with regard to 
demographic, clinical and immunological 
characteristics. Patients from urban areas 
were also compared with those from rural 
areas with regard to age, clinical presentation, 
tumour stage and CD4 count. To evaluate 
the statistical significance of univariate 
asso ciations, we used t-tests for normally 
distributed continuous variables and χ2 
tests for categorical variables. Continuous 
variables that were not normally distributed 
were categorised as quartiles for analysis. 
We developed logistic regression models 
to analyse the association of HAART with 
CD4 count, urban/rural residence, fungating 
lesions, ulceration and lymphoedema, and 
treatment delay, controlling for age and sex. 
We also analysed the association of clinical 
presentation with gender. For the logistic 
regression models, statistical significance 
was assessed on the basis of the 95% 
confidence intervals (CIs) around the odds 
ratios (ORs).
Results
All the 198 charts with a diagnosis of KS 
documented the HIV status of the patients; 
only four were HIV-negative. Of the 194 
HIV-positive patients, 168 (86.6%) were on 
HAART at the time of their first presentation 
to the oncology clinic.
Of the total sample, 183 had poor-risk 
disease, 4 had good-risk disease, and 7 could 
not be staged from the records in the clinical 
charts.
Of the 136 patients whose charts included 
the date of histological examination, 79 (58.1%) 
presented within 3 months of KS diagnosis 
(Table 1), including 64 of 117 patients on 
HAART (54.7%) and 15 of 19 not on HAART 
Table 1. Patient demographic and clinical characteristics according to HAART status
HAART (N=168, 
86.6%), n (%)
No HAART (N=26, 
13.4%), n (%)
Total (N=194,  
100.0%), n (%) p-value
Age quartiles (years) 0.03
2 - 29 36 (21.4) 12 (46.2) 48 (24.7)
30 - 35 41 (24.4) 4 (15.4) 45 (23.2)
36 - 41 50 (29.8) 3 (11.5) 53 (27.3)
42 - 81 41 (24.4) 7 (26.9) 48 (24.7)
Gender 0.40
Male 92 (54.8) 17 (65.4) 109 (56.2)
Female 76 (45.2) 9 (34.6) 85 (43.8)
Race 1.00
Black 167 (99.4) 26 (100.0) 193 (99.5)
Coloured 1 (0.6) 0 (0.0) 1 (0.5)
Residence 0.07
Urban 96 (57.1) 21 (80.8) 117 (60.3)
Rural 71 (42.3) 5 (19.2) 76 (39.2)
Unknown 1 (0.6) 0 (0.0) 1 (0.5)
Opportunistic 
infections
0.02
Tuberculosis 20 (11.9) 0 (0.0) 20 (10.3)
Oral Candida 0 (0.0) 1 (3.8) 1 (0.5)
Both 3 (1.8) 1 (3.8) 4 (2.1)
Unknown 145 (86.3) 24 (92.3) 169 (87.1)
Skin lesions 0.57
None 12 (7.1) 3 (11.5) 15 (7.7)
Localised 92 (54.8) 15 (57.7) 107 (55.2)
>1 skin site 60 (35.7) 7 (26.9) 67 (34.5)
Unknown 4 (2.4) 1 (3.8) 5 (2.6)
Oral lesions 0.10
Yes 43 (25.6) 11 (42.3) 54 (27.8)
No 125 (74.4) 15 (57.7) 140 (72.2)
Visceral lesions 0.03
Yes 8 (4.8) 4 (15.4) 12 (6.2)
No 159 (94.6) 21 (80.8) 180 (92.8)
Unknown 1 (0.6) 1 (3.8) 2 (1.0)
Lymphoedema 0.72
Yes 80 (47.6) 11 (42.3) 91 (46.9)
No 85 (50.6) 15 (57.7) 100 (51.5)
Unknown 2 (1.2) 0 (0.0) 2 (1.0)
Fungating lesions 0.66
Yes 23 (13.7) 5 (19.2) 28 (14.4)
No 142 (84.5) 21 (80.8) 163 (84.0)
Unknown 3 (1.8) 0 (0.0) 3 (1.5)
Ulceration 0.31
Yes 8 (4.8) 1 (3.8) 9 (4.6)
No 159 (94.6) 24 (92.3) 183 (94.3)
Unknown 1 (0.6) 1 (3.8) 2 (1.0)
Continued ...
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(78.9%), but the difference in timeliness 
of presentation did not reach statistical 
significance (p=0.09). The mean age at 
presentation was 36.6 (standard deviation 
(SD) 10.1) years. Females presen ted at a 
younger mean age than males, irrespective of 
HAART status, at 33.5 (SD 9.0) years v. 39.0 
(SD 10.3) years (p<0.001). Among patients 
on HAART, the mean age of females was 34.7 
years and that of males 39  years (p=0.003). 
Among patients who were HAART naive, 
the mean age of females was 23.7 years while 
that of males was 39 years (p=0.003). Males 
and patients on HAART were half as likely 
as females and patients not on HAART to 
present before their 30th birthday (p=0.03) 
(Table 2).
Patients who were HAART naive were 
more likely than those on HAART to 
reside in urban areas (80.8% v. 57.1%), 
but the difference did not reach statistical 
significance. Receiving HAART was not 
associated with extent of skin involvement, 
oral involvement, lymphoedema, fungating 
lesions or ulceration. However, HAART-
naive patients were three times as likely as 
those receiving HAART to have visceral 
involvement (15.4% v. 4.8%) (p=0.03). 
Opportunistic infections were mentioned 
in the charts of 25 of 194 patients. Of the 24 
who were diagnosed with tuberculosis (TB), 
all but one was receiving HAART.
Rural residents had higher CD4 counts 
than urban residents; they were also margi-
nally more recently diagnosed and more 
likely to have been seen in the oncology 
clinic <3 months after being diagnosed, but 
did not differ from urban residents in other 
respects (Table 3). In multivariate logistic 
regression analysis models that included 
CD4 count, age and gender, only age was 
associated with receiving HAART; patients 
aged ≥30 years were more than three times 
as likely to receive HAART as younger 
patients (Table 4). In a similar model, also 
including age and gender, residents of rural 
areas were more than three times as likely to 
receive HAART as residents of urban areas 
(Table 5).
Discussion
Among 194 KS patients seen in the ADH 
oncology clinic, nearly 87% were currently 
receiving HAART. In our multivariate 
models, which included gender, CD4 count, 
and treatment delay, only older age (≥30 
years) and rural residence were associated 
with receiving HAART.
For nearly a decade prior to 2003, the 
SA government’s AIDS denialist stance 
and lack of willingness to authorise and 
implement an antiretroviral programme 
contributed to high rates of HIV/
AIDS-related morbidity and mortality. 
During that period, the incidence of KS 
increased[9,12,13] and HIV-KS patients had 
a dismal 2-year survival rate of 20%. [14] 
Studies in Africa in the pre-HAART 
period repeatedly indicated a poorer 
disease profile in females than in males.[3] 
Prior to the AIDS epidemic, KS had been 
a predominantly male disease in Africa. 
This pattern also prevailed in North 
Table 1. (continued) Patient demographic and clinical characteristics according to 
HAART status
HAART (N=168, 
86.6%), n (%)
No HAART (N=26, 
13.4%), n (%)
Total (N=194,  
100.0%), n (%) p-value
Treatment plan <0.001
HAART 24 (14.3) 8 (30.8) 32 (16.5)
RT 39 (23.2) 5 (19.2) 44 (22.7)
Chemo 80 (47.6) 6 (23.1) 86 (44.3)
HAART and RT 2 (1.2) 3 (11.5) 5 (2.6)
 HAART and 
chemo
0 (0.0) 3 (11.5) 3 (1.5)
RT and chemo 17 (10.1) 1 (3.8) 18 (9.3)
Unknown 6 (3.6) 0 (0.0) 6 (3.1)
ACTG stage 0.25
None 3 (1.8) 1 (3.8) 4 (2.0)
T1 only 82 (48.8) 14 (53.8) 96 (48.5)
I1 only 4 (2.4) 0 (0.0) 4 (2.0)
S1 only 1 (0.6) 0 (0.0) 1 (0.5)
T1 + I1 55 (32.7) 6 (23.1) 61 (30.8)
Other 19 (11.3) 2 (7.7) 21 (10.6)
Unknown 4 (2.4) 3 (11.5) 7 (3.5)
Time from 
diagnosis to 
treatment (months)
0.29
<2 1 (0.6) 0 (0.0) 1 (0.5)
2 - 3 1 (0.6) 1 (3.8) 2 (1.0)
>3 166 (98.8) 25 (96.2) 191 (98.5)
Time from 
diagnosis to 
treatment (months)
0.16
<3 64 (38.1) 15 (57.7) 79 (40.7)
3 - 6 31 (18.5) 1 (3.8) 32 (16.5)
>6 22 (13.1) 3 (11.5) 25 (12.9)
Unknown 51 (30.4) 7 (26.9) 58 (29.9)
Year of 
histological testing
0.05
2007 0 (0.0) 1 (3.8) 1 (0.5)
2010 35 (20.8) 3 (11.5) 38 (19.6)
2011 82 (48.8) 15 (57.7) 97 (50.0)
Unknown 51 (30.4) 7 (26.9) 58 (29.9)
CD4 count (cells/µL) 0.05
0 - 125 40 (23.8) 4 (15.4) 44 (22.7)
126 - 250 46 (27.4) 6 (23.1) 52 (26.8)
≥251 79 (47.0) 13 (50.0) 92 (47.4)
Unknown 3 (1.8) 3 (11.5) 6 (3.1)
Chemo = chemotherapy; RT = radiotherapy.
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America and Europe. However, in Africa 
the male/female ratio was not as high, and 
females with HIV-KS had an earlier age 
at presentation, more extensive cutaneous 
involvement, more advanced tumour 
stage, more systemic symptoms, a greater 
frequency of opportunistic infections and 
a poorer prognosis than males.[2,3,13]
The national HAART roll-out programme 
began in SA in 2003. An early chart study of 
KS patients seen at the ADH oncology clinic 
in 2004 - 2006 showed that 44% had received 
HAART, and mean CD4 counts rose from 
200 cells/µL (2001 - 2003) to 218 cells/µL 
(2004 - 2006).[9]
In Uganda, HAART roll-out took place in the 
early 1990s, and the mean age of KS onset in 
females rose from 26.4 years (1991 - 1994) to 
a range of 28.1 - 29.6 years (1995 - 1997).[12] In 
a sample in which only 62% of patients had 
histologically confirmed KS, females had lower 
CD4 counts than males and differed from 
males in site of presentation, but did not 
differ in mean age at presentation, functional 
status, number of lesions, number of locations 
involved or tumour stage.[13] The investigators, 
therefore, questioned the relevance of gender 
to KS pathogenesis and prognosis.
More recently, the KAART study,[15] a 
randomised, prospective trial comparing 
HAART alone with combined HAART and 
chemotherapy regimens among HIV-KS 
patients in SA, demonstrated that 39% of 
patients improved on HAART alone. The 
treatment arms did not differ with regard 
to virological load, CD4 count, KS stage, 
overall survival or quality of life.
The relative efficacy of HAART alone 
is encouraging for those in settings where 
resources are limited. Our voluntary coun-
selling and testing (VCT) and anti retroviral 
enrolment programmes in KZN are improv-
ing, and with the plateau in our HIV epi-
demic,[16] a decrease in both KS incidence 
and severity may still be hoped for with just 
HAART in hand.
In recent years, the ADH oncology clinic 
has adopted a requirement of VCT and 
establishment of HIV status prior to referral. As 
a result, all our study participants had had their 
HIV status established before they were referred 
to the clinic, compared with 86% in the pre-
HAART era and 92% in the early HAART era.[9] 
Moreover, the patients in the current study were 
nearly twice as likely to be receiving HAART as 
those seen at the same site in the early HAART 
period[9] and those in a more recent survey of 
the HIV population in general.[17]
The mean age at presentation of our 
study participants on HAART was 37 years, 
slightly older than the 32 - 36-year range of 
patients studied in the early HAART era.[9,13]  
The mean CD4 count in this study was 266 
cells/µL, higher than the previous CD4 count 
of 218 cells/µL recorded in HIV-KS patients 
at this site.[9]
Female patients with HIV-KS, whether 
or not they were on HAART, continued to 
present at a younger age than males (Table 2). 
The persistence of earlier age at presentation 
in females may reflect the persistence of the 
HIV burden among very young females; in 
a 2009 nationwide survey, females in the 
15 - 24-year age group were more than three 
times as likely as males to be HIV-positive. 
The gender bias may even stronger in KZN, 
which has the highest HIV prevalence in SA; 
in a 2009 survey of pregnant women, the 
HIV prevalence was 39.5%.[18]
In our sample, both HAART use and CD4 
counts were in fact higher among females 
than among males, although the differences 
were not statistically significant (Table 2).
Recent studies in black African popu-
lations have found that females were more 
proactive than males in dealing with HIV, 
enrolling earlier and participating more 
broadly in HAART programmes.[19,20]
The finding that rural residents were more 
than three times as likely to use HAART 
as urban patients may reflect the successful 
implementation of national health policy to 
decentralise HAART initiation. It may also 
Table 2. Age group and CD4 count group according to HAART status, stratified by gender
HAART,
n (%)
No HAART,
n (%)
Total,
n (%) p-value
Males 92 (84.4) 17 (15.6) 109 (100.0)
Age quartiles (years) 0.26
2 - 29 13 (14.1) 5 (29.4) 18 (16.5)
30 - 35 22 (23.9) 2 (11.8) 24 (22.0)
36 - 41 27 (29.3) 3 (17.6) 30 (27.5)
42 - 81 30 (32.6) 7 (41.2) 37 (33.9)
CD4 count (cells/µL) 0.39
0 - 125 22 (23.9) 4 (23.5) 26 (23.9)
126 - 250 27 (29.3) 3 (17.6) 30 (27.5)
≥251 40 (43.5) 8 (47.1) 48 (44.0)
Unknown 3 (3.3) 2 (11.8) 5 (4.6)
 Time from diagnosis to treatment 
(months)
0.43
<3 37 (40.2) 9 (52.9) 46 (42.2)
3 - 6 17 (18.5) 1 (5.9) 18 (16.5)
>6 12 (13.0) 1 (5.9) 13 (11.9)
Unknown 26 (28.3) 6 (35.3) 32 (29.4)
Females 76 (89.4) 9 (10.6) 85 (100.0)
Age quartiles (years) 0.03
2 - 29 23 (30.3) 7 (77.8) 30 (35.3)
30 - 35 19 (25.0) 2 (22.2) 21 (24.7)
36 - 41 23 (30.3) 0 (0.0) 23 (27.1)
42 - 81 11 (14.5) 0 (0.0) 11 (12.9)
CD4 count (cells/µL) 0.01
0 - 125 18 (23.7) 0 (0.0) 18 (21.2)
126 - 250 19 (25.0) 3 (33.3) 22 (25.9)
≥251 39 (51.3) 5 (55.6) 44 (51.8)
Unknown 0 (0.0) 1 (11.1) 1 (1.2)
 Time from diagnosis to treatment 
(months)
0.15
<3 27 (35.5) 6 (66.7) 33 (38.8)
3 - 6 14 (18.4) 0 (0.0) 14 (16.5)
>6 10 (13.2) 2 (22.2) 12 (14.1)
Unknown 25 (32.9) 1 (11.1) 26 (30.6)  
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reflect self-selection by health-conscious or 
health-motivated individuals from rural areas 
who seek healthcare in an urban oncology 
clinic. Our sample may represent the tip of 
an iceberg, floating above an HIV-KS patient 
population that is receiving either no care at 
all or sole care from traditional providers. We 
are currently developing a study to identify 
and address barriers to timely diagnosis and 
effective treatment of HIV-KS in KZN.
Most patients in the study presented at the 
oncology clinic ≥3 months after histological 
diagnosis of KS. We were unable to determine 
how much of the delay was due to patients’ 
reluctance to seek healthcare and how much 
to an overburdened healthcare system in 
which patients who actively seek care must 
wait months to receive it. Neither HAART 
nor location of residence was associated with 
extent of skin involvement, oral involvement, 
lymphoedema, fungating lesions or ulceration 
(data not shown). HAART-naive patients 
were, however, three times as likely to have 
visceral involvement as those receiving 
HAART (15.4% v. 4.8%) (p=0.03).
Table 3. Demographic and clinical factors according to rural/urban residence
Urban
(N=117, 60.6%),
n (%)
Rural
(N=76, 39.4%),
n (%)
Total
(N=193, 100.0%),
n (%) p-value
Age quartiles (years) 0.24
2 - 29 29 (24.8) 19 (25.0) 48 (24.9)
30 - 35 32 (27.4) 13 (17.1) 45 (23.3)
36 - 41 27 (23.1) 26 (34.2) 53 (27.5)
42 - 81 29 (24.8) 18 (23.7) 47 (24.4)
Gender 0.66
Male 67 (57.3) 41 (53.9) 108 (56.0)
Female 50 (42.7) 35 (46.1) 85 (44.0)
Oral lesions 0.33
Yes 36 (30.8) 18 (23.7) 54 (28.0)
No 81 (69.2) 58 (76.3) 139 (72.0)
Visceral lesions 0.29
Yes 9 (7.7) 3 (3.9) 12 (6.2)
No 106 (90.6) 73 (96.1) 179 (92.7)
Unknown 2 (1.7) 0 (0.0) 2 (1.0)
Lymphoedema 0.12
Yes 52 (44.4) 39 (51.3) 91 (47.2)
No 64 (54.7) 35 (46.1) 99 (51.3)
Unknown 0 (0.0) 2 (2.6) 2 (1.0)
Fungating lesions 0.20
Yes 18 (15.4) 10 (13.2) 28 (14.5)
No 98 (83.8) 64 (84.2) 162 (83.9)
Unknown 0 (0.0) 2 (2.6) 2 (1.0)
Ulceration 0.28
Yes 7 (6.0) 2 (2.6) 9 (4.7)
No 108 (92.3) 74 (97.4) 182 (94.3)
Unknown 2 (1.7) 0 (0.0) 2 (1.0)
Time from diagnosis to 
treatment (months)
0.06
<3 46 (39.3) 33 (43.4) 79 (40.9)
3 - 6 16 (13.7) 16 (21.1) 32 (16.6)
>6 12 (10.3) 12 (15.8) 24 (12.4)
Unknown 43 (36.8) 15 (19.7) 58 (30.1)
Year of histological 
examination
0.06
2007 1 (0.9) 0 (0.0) 1 (0.5)
2010 19 (16.2) 18 (23.7) 37 (19.2)
2011 54 (46.2) 43 (56.6) 97 (50.3)
Unknown 43 (36.8) 15 (19.7) 58 (30.1)
CD4 count (cells/µL) 0.04
0 - 125 33 (28.2) 11 (14.5) 44 (22.8)
126 - 250 32 (27.4) 20 (26.3) 52 (26.9)
≥251 47 (40.2) 44 (57.9) 91 (47.2)
Unknown 5 (4.3) 1 (1.3) 6 (3.1)  
Table 4. Association between receiving 
HAART and CD4 count, age, and gender
OR 95% CI
CD4 count (cells/µL)
0 - 125 1.0 Referent
126 - 250 0.6 0.2 - 2.4
≥251 0.5 0.2 - 1.8
Unknown 0.1 0.0 - 0.9
Age quartiles (years)
2 - 29 1.0 Referent
30 - 35 3.6 1.0 - 12.8
36 - 41 3.6 1.5 - 24.8
42 - 81 3.1 1.0 - 10.2
Gender
Male 1.0 Referent
Female 2.0 0.8 - 5.4
Table 5. Association between receiving 
HAART and rural/urban residence, age, 
and gender 
OR 95% CI
Residence
Urban 1.0 Referent
Rural 3.3 1.1 - 9.5
Age quartiles (years)
2 - 29 1.0 Referent
30 - 35 4.8 1.3 - 17.3
36 - 41 6.3 1.6 - 25.3
42 - 81 3.3 0.9 - 8.4
Gender
Male 1.0 Referent
Female 2.1 0.8 - 5.6
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Study limitations
Our limited determination of associations should not lead to 
underestimation of the true value of HAART. Our sampling frame 
may have been affected by referral bias. Patients managed successfully 
for KS-related conditions at other healthcare facilities may not be 
represented in the sample that is eventually referred to the oncology 
clinic.
In addition, because the overwhelming majority of patients at the 
oncology site had advanced disease, we could not evaluate the effect 
of HAART use on tumour stage.
We also could not evaluate an association between HAART use and 
opportunistic infections. The most commonly documented infection 
among our patients was TB. The presentations of pulmonary TB 
and KS disseminated to the lung may be very similar in terms of 
respiratory tract signs and the presence of B symptoms (fever, loss 
of weight, fatigue). SA’s high TB prevalence may prompt a diagnosis 
in favour of this disease without further investigation for HIV-KS. 
However, of 24 patients with TB in our sample, 23 were receiving 
HAART, and 20 had been diagnosed with TB before they presented 
at the oncology clinic. Further research is needed on the relationship 
between KS and TB and the true prevalence of dual pathology.
Conclusion
The use of HAART in SA has improved care for HIV-KS patients. In 
our sample, all patients had documented HIV status, and 86.6% had 
commenced HAART before their visit to the oncology clinic. Mean 
age at presentation has increased, both for the group as a whole and 
for females in particular. Mean CD4 cell counts have risen. If our 
sample is representative of the HIV-KS population in KZN, females 
are no longer shouldering a disproportionate burden of disease. 
Furthermore, the benefits of HAART appear to be equally distributed 
between the rural and urban settings. With HAART in hand, we have 
reason to hope that we can improve the lot of HIV-KS patients.
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